Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Under the collaboration signed in 2001
Subscribe to our email newsletter
Karo Bio has reported that in the beginning of September 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the two companies.
The company said that the primary objective of the collaboration is to identify and select development candidates for treatment of inflammatory diseases, focusing on the liver X receptor (LXR) as target receptor. Karo Bio and Wyeth initially entered the collaboration in 2001.
Per Olof Wallstrom, president and CEO of Karo Bio, said: “We are pleased that this exciting LXR program continues within Wyeth. Since Wyeth will perform all future research and development, Karo Bio will not put any more internal resources into the project and will therefore not receive any further research funding from Wyeth. However, the Collaboration, Research and License Agreement between the companies shall remain in effect.”